Loading
TAPPAS tested whether adding an antibody against endoglin, a protein on the abnormal blood vessel cells that make up angiosarcoma, would improve on the standard tablet pazopanib; it did not, and the trial was stopped for futility.
Angiosarcoma cells express endoglin (CD105), and TRC105 (carotuximab) is an antibody against it that had shown responses in combination with pazopanib in an earlier study. TAPPAS was an adaptive phase 3 trial randomising 123 patients with advanced angiosarcoma, cutaneous and non-cutaneous, to pazopanib with or without TRC105, with progression-free survival as the primary endpoint.
An interim analysis found no improvement in progression-free survival with the combination and the trial was stopped for futility. It remains one of the few randomised trials ever completed in angiosarcoma, and its control arm data on pazopanib are a reference for the disease.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
128 enrolled.
114 evaluable of 123 randomised
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (blinded independent review)primary | Carotuximab (TRC105) + pazopanib | 61 | 4.2 months | 0.98 (0.52 to 1.84) | 0.95 | link |
| Pazopanib alone | 53 | 4.3 months | ||||
| Epistaxis (all grades) | Carotuximab (TRC105) + pazopanib | 61 | 56% | - | - | link |
| Pazopanib alone | 53 | 4% | ||||
| Anaemia (all grades) | Carotuximab (TRC105) + pazopanib | 61 | 44% | - | - | link |
| Pazopanib alone | 53 | 9% |
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Monoclonal antibodies and the tag subtype-trials.
Shares Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.